Insulet to switch CFO after Acton move, new CEO
Photo | Courtesy
Wayde McMillan
Acton-based manufacturer of insulin management systems Insulet Corp. has hired a new chief financial officer.
Wayde McMillan, a 20-year veteran of finance and accounting, will officially take over March 1 from Michael Levitz. McMillan will join the company in February with Levitz remaining in an advisory capacity for a short period of time.
McMillan boasts a career with multi-billion dollar companies and small start-up ventures, most recently as chief financial officer and vice president of finance of the minimally invasive therapies group at Ireland-based Medtronic, which has offices in the MetroWest area.
While there, he played a key role in the company’s $50 billion acquisition of Covidien plc in 2015.
McMillan’s arrival comes shortly after CEO Shacey Petrovic assumed the top role in the company effective Jan. 1 after outgoing CEO Patrick Sullivan’s retirement.
“We are excited to welcome a leader of Wayde’s caliber to Insulet as the Company transitions to profitability, expands internationally, and enters its next phase of rapid growth,” Petrovic said in a statement. “Wayde has significant expertise scaling large organizations and a thorough understanding of the strategies we are pursuing globally to accelerate growth and build on our strong foundation.”
According to Levitz’ Linkedin profile, he began working as the head of Insulet’s finances in May 2015.
The company recently moved its headquarters from Billerica to a $100 million facility in Acton.
WBJ Web Partners
Most Recent
Most Recent
0 Comments